Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2017 ) > List of Articles

REVIEW ARTICLE

Liver Support Devices: Bridge to Transplant or Recovery

Nandhini Anamthuruthil Joseph, Lakshmi Krishna Kumar

Keywords : Artificial liver, bioartificial liver, liver assist devices, liver failure

Citation Information : Joseph NA, Kumar LK. Liver Support Devices: Bridge to Transplant or Recovery. Indian J Respir Care 2017; 6 (2):807-812.

DOI: 10.4103/ijrc.ijrc_11_17

License: CC BY-NC-SA 3.0

Published Online: 02-12-2022

Copyright Statement:  Copyright © 2017; Indian Journal of Respiratory Care.


Abstract

Liver failure, whether acute or acute on chronic, is a devastating disease with a very high mortality and morbidity. The recent therapeutic advances, especially liver transplant, have given reason for optimism to the ever-rising population affected by this disease. However, scarcity of organs and lack of resources make this an option that only few can afford. The hunt for an artificial device to assist or replace the functions of the liver has been on the rise since the past 40 years. These devices are classified into artificial and bioartificial liver (BAL) assist devices. Artificial liver devices such as molecular adsorbent recirculating system, Prometheus, single-pass albumin dialysis, and selective plasma filtration therapy are mostly aimed at taking over the blood purification systems of the liver. BAL-assisted devices incorporate hepatic cell lines to obtain a more comprehensive coverage of the complex functions of the liver. These include extracorporeal liver assist device, modular extracorporeal liver support, HepatAssist, and Amsterdam Medical Centre-BAL. Development of an ideal liver assist device has been difficult due to the complexity of the functions of the organ. The initial studies on these devices are promising but inconclusive. Therapeutic plasma exchange seems to have a very favorable profile in the treatment of these patients and has been successfully used in a large number of patients. To arrive at a more definitive conclusion of the usefulness of these devices in the management of liver failure, large randomized multicentric studies with more objective end points need to be carried out. A literature review was performed using PubMed and library searches to collect the recent studies in this regard. This review aims to provide a myopic view of the advances that have been made in the development and usefulness of these liver assist devices.


HTML PDF Share
  1. Data (Charts and Tables) – Global Observatory on Donation and Transplantation. Available from: http://www.transplant-observatory.org/ data-charts-and-tables. [Last retrieved on 2017 Apr 27].
  2. Mushlin PS, Gelman S. Hepatic physiology and pathophysiology. In: Miller RD, editor. Miller’s Anesthesia. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 428-31.
  3. Mushlin PS, Gelman S. Hepatic physiology and pathophysiology. In: Miller RD, editor. Miller’s Anesthesia. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 412-24.
  4. Chapman RW, Collier JD, Hayes PC. Liver and biliary tract disease. In: Boon NA, Colledge NR, Walker BR, Hunter JA, editors. Davidson’s Principles and Practices of Medicine. 20th ed. Philadelphia: Churchill Livingstone; 2006. p. 954-5.
  5. Bernal W, Wendon J. Acute liver failure. N Engl J Med 2014;370:1170-1
  6. Rozga J. Liver support technology – An update. Xenotransplantation 2006;13:380-9.
  7. O’Grady J. Personal view: Current role of artificial liver support devices. Aliment Pharmacol Ther 2006;23:1549-57.
  8. Puri P, Anand AC. Liver support devices. Med Update 2012;22:489-93.
  9. Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int 2014;34:42-8.
  10. O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988;94(5 Pt 1):1186-92.
  11. Gimson AE, Braude S, Mellon PJ, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982;2:681-3.
  12. Coltart I, Tranah TH, Shawcross DL. Inflammation and hepatic encephalopathy. Arch Biochem Biophys 2013;536:189-96.
  13. Liu CT, Chen TH, Cheng CY. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apher 2013;28:430-4.
  14. Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 2016;64:69-78.
  15. Karvellas CJ, Subramanian RM. Current evidence for extracorporeal liver support systems in acute liver failure and acute-on-chronic liver failure. Crit Care Clin 2016;32:439-51.
  16. Iwai H, Nagaki M, Naito T, Ishiki Y, Murakami N, Sugihara J, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998;26:873-6.
  17. Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian S, Wright H, et al. The effect of total plasma exchange on fulminant hepatic failure. J Clin Apher 2006;21:96-9.
  18. Phua J, Lee KH. Liver support devices. Curr Opin Crit Care 2008;14:208-15.
  19. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997;3:282-6.
  20. Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999;23:829.
  21. Poyck PP, van Wijk AC, van der Hoeven TV, de Waart DR, Chamuleau RA, van Gulik TM, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008;48:266-75.
  22. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999;23:319-30.
  23. Bachli EB, Schuepbach RA, Maggiorini M, Stocker R, Müllhaupt B, Renner EL. Artificial liver support with the molecular adsorbent recirculating system: Activation of coagulation and bleeding complications. Liver Int 2007;27:475-84.
  24. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002;26:103-10.
  25. Mitzner SR, Stange J, Klammt S, Koball S, Hickstein H, Reisinger EC. Albumin dialysis MARS: Knowledge from 10 years of clinical investigation. ASAIO J 2009;55:498-502.
  26. Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology 2013;57:1153-62.
  27. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, et al. Prometheus – A new extracorporeal system for the treatment of liver failure. J Hepatol 2003;39:984-90.
  28. Rifai K, Manns MP. Review article: Clinical experience with Prometheus. Ther Apher Dial 2006;10:132-7.
  29. Krisper P, Stauber RE. Technological insight: Artificial extracorporeal liver support – How does Prometheus compare with MARS? Nat Rev Nephrol 2007;3:267-76.
  30. Sponholz C, Matthes K, Rupp D, Backaus W, Klammt S, Karailieva D, et al. Molecular adsorbent recirculating system and single-pass albumin dialysis in liver failure – A prospective, randomised crossover study. Crit Care 2016;20:2.
  31. Boonsrirat U, Tiranathanagul K, Srisawat N, Susantitaphong P, Komolmit P, Praditpornsilpa K, et al. Effective bilirubin reduction by single-pass albumin dialysis in liver failure. Artif Organs 2009;33:648-53.
  32. Rozga J, Umehara Y, Trofimenko A, Sadahiro T, Demetriou AA. A novel plasma filtration therapy for hepatic failure: Preclinical studies. Ther Apher Dial 2006;10:138-44.
  33. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-51.
  34. Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: System modifications and clinical impact. Transplantation 2002;74:1735-46.
  35. Watanabe FD, Mullon CJ, Hewitt WR, Arkadopoulos N, Kahaku E, Eguchi S, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225:484-91.
  36. Demetriou AA, Brown RS Jr., Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-7.
  37. Pless G. Artificial and bioartificial liver support. Organogenesis 2007;3:20-4.
  38. Poyck PP, Pless G, Hoekstra R, Roth S, Van Wijk AC, Schwartländer R, et al. In vitro comparison of two bioartificial liver support systems: MELS CellModule and AMC-BAL. Int J Artif Organs 2007;30:183-91.
  39. Liu JP, Gluud LL, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004;(1):CD003628.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.